Study #2021-0341
CK0804-101-1: Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib
MD Anderson Study Status
Enrolling
Treatment Agent
CK0804
Description
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis
Study phase:
Phase I
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.